We’re closing in on three years now and it’s becoming hard to believe there was a market before COVID-19. We can barely remember it. Cannabis was a thing briefly,…
Revive Therapeutics
Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Revive Therapeutics (RVV.C) joined the AdvisorShares Psychedelics ETF (PSIL.NYSE) today, in time for its launch, according to a press release. If you’re not entirely sure what an ETF…
Revive Therapeutics (RVV.C) announced they are entering into an exclusive license agreement with Puerto Rico Science Technology and Research Trust (PRSTRT) for the intellectual property titled ‘Biologically Active Ganoderma…
Revive Therapeutics (RVV.C) provided an update on their psychedelics development and clinical programs focused on psilocybin, which they are aiming to use to treat a number of disorders. Revive…
Revive Therapeutics (RVV.C) has provided an update on the Company’s US Food and Drug Administration (FDA) Phase 3 clinical trial to evaluate the safety and efficacy of bucillamine in…
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and…
Steady as she goes It’s been a rough couple of quarters for the psychedelics sector at large. Some companies have been able to avoid the correction, but for the…
Revive Therapeutic (RVV.C) announced they have entered into an agreement with the University of Health Sciences Antigua (UHSA) to collaborate with Revive on their novel psychedelic-assisted therapies and pioneering…
Revive Therapeutics (RVV.C) entered into a memorandum of understanding with Indian pharmaceutical company, Supriya Lifescience, which includes manufacturing, clinical registration and commercialization for Bucillamine, according to a press release….